Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma-Reply

Affiliations

¹ Canadian Cancer Trials Group, Kingston, Ontario, Canada.
² Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Comment

Bingshu E Chen et al. JAMA Oncol. 2017.

. 2017 Oct 1;3(10):1431.

doi: 10.1001/jamaoncol.2017.2023.

¹ Canadian Cancer Trials Group, Kingston, Ontario, Canada.
² Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

No abstract available

Comment on

Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.
Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Siu LL, et al. JAMA Oncol. 2017 Feb 1;3(2):220-226. doi: 10.1001/jamaoncol.2016.4510. JAMA Oncol. 2017. PMID: 27930762
Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma.
Cheng D, Pak K, Wei LJ. Cheng D, et al. JAMA Oncol. 2017 Oct 1;3(10):1430-1431. doi: 10.1001/jamaoncol.2017.0737. JAMA Oncol. 2017. PMID: 28750125 Free PMC article. No abstract available.